44.6 and 40.7 percent of patients in the high-dose and standard-dose groups, respectively, died during six months of follow-up<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Dec. 19, 2025 (HealthDay News) — No benefit of high-dose versus standard-dose rifampin is seen among adults with tuberculosis meningitis, according to a study published online Dec. 17 in the New England<\/em> Journal of Medicine<\/em>.<\/p>\n David B. Meya, M.B., Ch.B., Ph.D., from Makerere University in Uganda, and colleagues conducted a randomized, placebo-controlled clinical trial involving adults with tuberculosis meningitis in Indonesia, South Africa, and Uganda to examine whether high-dose rifampin could improve survival outcomes. Participants with and without HIV coinfection were randomly assigned to receive eight weeks of standard daily isoniazid, rifampin (10 mg\/kg body weight), ethambutol, and pyrazinamide plus either additional rifampin (for a cumulative dose of 35 mg\/kg; high-dose group) or matched placebo (standard-dose group; 249 and 250 participants, respectively).<\/p>\n The researchers found that 109 (44.6 percent) and 100 participants (40.7 percent) in the high-dose and standard-dose groups, respectively, died during six months of follow-up (hazard ratio, 1.17; 95 percent confidence interval, 0.89 to 1.54). The median time to death was 13 and 24 days in the high-dose and standard-dose groups, respectively, among those who died within six months. Drug-induced liver injury occurred in 8.0 and 4.4 percent of participants in the high-dose and standard-dose groups, with no deaths from drug-induced liver injury.<\/p>\n “It was, of course, disappointing that this is not the solution. But these are important results — we now know we need to take a different path. That\u2019s how science works,” coauthor Reinout van Crevel, M.D., Ph.D., from the University of Oxford in the United Kingdom, said in a statement.<\/p>\n One coauthor disclosed financial ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n